COVID-19 breakthrough infection among vaccinated individuals: A cross-sectional study
DOI:
https://doi.org/10.3126/ajms.v13i7.44473Keywords:
Breakthrough infection, Comorbidities, COVID-10 vaccine, COVID-19Abstract
Background: A cross-sectional study was carried out in urban area. The primary outcome of the study was the proportion of breakthrough infection in vaccinated subjects, which was defined as any COVID-19 infection occurring ≥30 days after receiving both the doses of either of the vaccine(s).
Aims and Objectives: The aims of this study were to determine prevalence of COVID-19 breakthrough infection among COVID 19 vaccinated patients, (1) to study demographic factors affecting breakthrough infection and (2) to compare the proportion of breakthrough infection among Covishield and Covaxin recipients.
Materials and Methods: The subjects were selected by systematic random sample method from available vaccination record. A questionnaire was administered in local language containing demographic information and COVID-related information. Nasopharyngeal swab was taken by trained Interns with all necessary precautions, RT-PCR swab was labeled and sent to PCR laboratory in cold chain for testing.
Results: A total 445 subjects were tested for COVID-19. Subjects included 290 (65.2%) males and 155 (34.8%) females. Maximum cases were from age group of 21–30 year (23.4%). The mean age was found to be 43 year. About 8.85% subjects test result came positive despite taking two doses of either COVID vaccine. Breakthrough infection was more among males than females. Covaxin recipient subjects showed marginally higher percentage of breakthrough infection (9.1%) than Covishield. Out of the 39 breakthrough infections, 16 subjects were having comorbidities. Maximum breakthrough infection was seen in subjects having diabetes mellitus and hypertension both and hypertension alone (1.6%).
Conclusion: A prevalence of 8.8% of COVID-19 breakthrough infection was reported in our study among fully vaccinated subjects after 30 days of last vaccine dose. Males are at higher risk of getting infection. People with comorbidities are at higher risk of breakthrough infection and hospitalization.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).